EUVIMEDEUVIMED entdecken
BeobachtungsstudieMultizentrische Studie

Early therapeutic drug monitoring helps to identify inflammatory bowel disease patients with a high risk to fail thiopurine treatment

Debbie S Deben iD, Bjorn Winkens, Sofia A W van Moorsel, Brigit P C van Oijen, Paul Bus, Marieke J Pierik, Melek Simsek, Nanne K H de Boer, Mathie P G Leers, Dennis R Wong, Adriaan A van Bodegraven

British Journal of Clinical Pharmacology · 2024

DOI: 10.1111/bcp.16219 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift British Journal of Clinical Pharmacology, 2024. Verfasst von Debbie S Deben und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Pharmacy, Clinical Pharmacology and Toxicology, Zuyderland Medical Centre, Sittard-Geleen/Heerlen, Netherlands. Hauptthemen laut MEDLINE: Mercaptopurine, Drug Monitoring, Inflammatory Bowel Diseases, Azathioprine. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 34 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

Conventional thiopurines (azathioprine and mercaptopurine) remain standard therapy to maintain steroid sparing remission in inflammatory bowel disease (IBD), but are regularly discontinued due to adverse drug reactions (ADRs). Measurement of the metabolites 6‐thioguanine nucleotides (6‐TGN), 6‐methylmercaptopurine ribonucleotides (6‐MMPR) and the 6‐MMPR/6‐TGN ratio, may predict the development of these ADRs. Our aim was to evaluate whether early thiopurine metabolite measurements were associated with clinical outcomes.

Methods

A post‐hoc analysis was conducted of a multicentre, prospective, observational study on thiopurine‐induced hepatotoxicity. IBD patients who initiated thiopurine therapy were included and thiopurine metabolite concentrations were assessed after 7 days (±1) (T1). Patients were monitored for 12 weeks to document the occurrence of ADRs, early treatment discontinuation and effectiveness.

Results

In total, 181 patients were evaluated. At T1, 6‐MMPR concentrations and 6‐TGN/6‐MMPR ratios were independently related to treatment discontinuation within 12 weeks after correction for sex, age and body mass index (BMI) ( P = .034 and .002, respectively). The largest effects were observed for 6‐MMPR ≥3000 pmol/8 × 10 8 RBC and 6‐TGN/6‐MMPR ratio ≥17. Furthermore, 6‐MMPR concentrations and 6‐TGN/6‐MMPR ratios at T1 were independently related to skewed metabolism at steady state (Week 8, 6‐MMPR/‐6TGN ratio ≥11 and ≥20) (both P < .001). The occurrence of ADRs and effectiveness were not independently related to T1 thiopurine metabolite concentrations.

Conclusions

Thiopurine metabolite concentrations at T1 were related to early treatment discontinuation and skewed metabolism at steady state, but not to effectiveness, helping to identify patients with a high risk of thiopurine treatment failure.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MercaptopurineDrug MonitoringInflammatory Bowel DiseasesAzathioprineGuanine NucleotidesHumansMaleFemaleAdultProspective StudiesMiddle AgedThionucleotidesImmunosuppressive AgentsChemical and Drug Induced Liver InjuryYoung AdultMethylthioinosineAgedThioinosine

Stichwörter der Autor:innen

inflammatory bowel disease (IBD)therapeutic drug monitoring (TDM)thiopurines

Substanzen

MercaptopurineAzathioprineGuanine Nucleotides6-thioguanylic acidThionucleotidesImmunosuppressive Agents6-methylthiopurine ribonucleoside-5'-phosphateMethylthioinosineThioinosine

Autor:innen und Institutionen

  • Department of Clinical Pharmacy, Clinical Pharmacology and Toxicology, Zuyderland Medical Centre, Sittard-Geleen/Heerlen, Netherlands.
  • Department of methodology and statistics, CAPHRI Care and Public Health Research Institute, Maastricht University Medical Center, Maastricht, Netherlands.
  • Department of Pharmacy, Jeroen Bosch Hospital, 's-Hertogenbosch, Netherlands.
  • Department of Clinical Pharmacy, Bernhoven Hospital, Uden, Netherlands.
  • Department of Gastroenterology and Hepatology, Laurentius Hospital, Roermond, Netherlands.
  • Department of Gastroenterology and Hepatology, Maastricht University Medical Center, Maastricht, Netherlands.

ORCID-Profile: Debbie S Deben

Zitieren

APA

Deben, D. S., Winkens, B., van Moorsel, S. A. W., van Oijen, B. P. C., Bus, P., Pierik, M. J., Simsek, M., de Boer, N. K. H., Leers, M. P. G., Wong, D. R., & van Bodegraven, A. A. (2024). Early therapeutic drug monitoring helps to identify inflammatory bowel disease patients with a high risk to fail thiopurine treatment. British Journal of Clinical Pharmacology. https://doi.org/10.1111/bcp.16219

Vancouver

Deben DS, Winkens B, van Moorsel SAW, van Oijen BPC, Bus P, Pierik MJ, et al. Early therapeutic drug monitoring helps to identify inflammatory bowel disease patients with a high risk to fail thiopurine treatment. British Journal of Clinical Pharmacology. 2024. doi:10.1111/bcp.16219

BibTeX
@article{Deben2024,
  author = {Deben, Debbie S and Winkens, Bjorn and van Moorsel, Sofia A W and van Oijen, Brigit P C and Bus, Paul and Pierik, Marieke J and Simsek, Melek and de Boer, Nanne K H and Leers, Mathie P G and Wong, Dennis R and van Bodegraven, Adriaan A},
  title = {Early therapeutic drug monitoring helps to identify inflammatory bowel disease patients with a high risk to fail thiopurine treatment},
  journal = {British Journal of Clinical Pharmacology},
  year = {2024},
  doi = {10.1111/bcp.16219}
}
Kostenlos starten →